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SUMMARY
Targeting immune checkpoints such as the one mediated by programmed cell death protein 1 
(PD-1) and its ligand PD-L1 have been approved for treating human cancers with durable 
clinical benefit 1,2. However, many cancer patients fail to respond to anti-PD-1/PD-L1 
treatment, and the underlying mechanism(s) is not well understood 3–5. Recent studies 
revealed that response to PD-1/PD-L1 blockade might correlate with PD-L1 expression 
levels in tumor cells 6,7. Hence, it is important to mechanistically understand the pathways 
controlling PD-L1 protein expression and stability, which can offer a molecular basis to 
improve the clinical response rate and efficacy of PD-1/PD-L1 blockade in cancer patients. 
Here, we report that PD-L1 protein abundance is regulated by cyclin D-CDK4 and the Cullin 
3SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4/6 in vivo 
elevates PD-L1 protein levels largely through inhibiting cyclin D-CDK4-mediated 
phosphorylation of SPOP, thereby promoting SPOP degradation by APC/CCdh1. Loss-of-
function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, 
leading to increased PD-L1 levels and reduced numbers of tumor-infiltrating lymphocytes 
(TILs) in mouse tumors and in primary human prostate cancer specimens. Notably, 
combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumor 
regression and dramatically improves overall survival rates in mouse tumor models. Our 
study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell 
cycle kinase and reveals the potential for using combination treatment with CDK4/6 
inhibitors and PD-1/PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for 
human cancers.
Deregulated cell cycle progression is a hallmark of human cancer, and targeting cyclin-
dependent kinases (CDKs) to block cell proliferation has been validated as an effective anti-
cancer therapy 8. Although it has been reported that PD-L1 expression can be regulated at 
both transcriptional 9,10 and post-translational levels 11,12, it remains unclear whether PD-L1 
stability is regulated under physiological conditions such as during cell cycle progression. 
We found that PD-L1 protein abundance fluctuated during cell cycle in multiple human 
cancer cell lines, peaking in M/early G1 phases, followed by a sharp reduction in late G1/S 
phases (Fig. 1a–d; Extended Data Fig. 1a–g). Elevated PD-L1 protein abundance was also 
observed in multiple mouse tumor-derived cell lines arrested in M phase by nocodazole or 
taxol 13 (Extended Data Fig. 1h–m).
Cyclin-dependent kinases play crucial roles in regulating the stability of cell cycle-related 
proteins during cell cycle progression 14,15. Therefore, we adopted a genetic method to 
ablate each major cyclin and found that ablating all three D-type cyclins (D1, D2 and D3), 
but not cyclin A (A1 and A2) nor cyclin E (E1 and E2), strongly elevated PD-L1 protein 
abundance in mouse embryonic fibroblasts (MEFs) (Fig. 2a and Extended Data Fig. 2a–e). 
Using MEFs lacking individual D-type cyclins, we observed that depletion of cyclin D1, and 
to a lesser extent cyclin D2 or D3, upregulated PD-L1 protein levels (Fig. 2b, c). Conversely, 
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reintroduction of cyclin D1, and to a lesser extent cyclin D2 or D3, suppressed PD-L1 
protein abundance in cyclin D1−/−D2−/−D3−/− MEFs (Extended Data Fig. 2f). In further 
support of a physiological role for cyclin D1 in negatively regulating PD-L1 protein level in 
vivo, mammary tumors arising in cyclin D1−/− MMTV-Wnt-1 or MMTV-c-Myc mice 
displayed elevated PD-L1 protein levels, as compared to tumors arising in cyclin D1+/+ 
animals (Fig. 2d and Extended Data Fig. 2g).
Depletion of cyclin D catalytic partner, the cyclin-dependent kinase 4 (CDK4) 16, but not 
CDK6 16 nor the cyclin A and cyclin E binding-partner, CDK2 17, also increased PD-L1 
protein abundance in cells (Fig. 2e, f; Extended Data Fig. 2h–j). Conversely, ectopic 
expression of wild-type CDK4, but not kinase-dead N158F mutant, decreased PD-L1 levels 
(Extended Data Fig. 2k, l). Furthermore, treatment of multiple cancer cell lines with two 
different selective inhibitors of CDK4/6 kinase, palbociclib or ribociclib 8, upregulated PD-
L1 protein abundance and stability even in pRB knock-down cells (Fig. 2g, h; Extended 
Data Fig. 2m–q).
Rb is frequently inactivated in human cancers 18,19. In agreement with previous reports 20,21, 
we found that Rb-deficient cancer cells often displayed high levels of cyclin D-CDK4/6 
inhibitor, p16INK4a. Consistent with the notion that cyclin D1-CDK4 kinase suppresses PD-
L1 levels, we observed that upregulation of 16INK4 correlated with elevated PD-L1 levels. 
Moreover, in Rb-proficient/p16-low cancer cell lines, higher PD-L1 levels correlated with 
relatively low CDK4 expression (Extended Data Fig. 2r). In addition, ectopic expression of 
p16INK4 in Rb-proficient/p16-low cell lines (MCF7 and T47D) or Rb-deficient/p16-low cell 
line (HLF) elevated PD-L1 protein abundance (Extended Data Fig. 2s–u), while depletion of 
p16INK4 in Rb-deficient/p16-high cell lines (MDA-MB-436, BT549, and HCC1937) had an 
opposite effect (Extended Data Fig. 2v–x), further documenting an inverse correlation 
between the CDK4 activity and PD-L1 expression.
To extend these observations to an in vivo setting, we treated MMTV-ErbB2 mice bearing 
autochthonous breast cancers, or mice carrying allografts of murine MC38 or B16-F10 
cancer cell lines with palbociclib, and monitored PD-L1 levels. Inhibition to CDK4/6 led a 
significant upregulation of PD-L1 in all these cancer models, which was accompanied by a 
reduction in the number of infiltrating CD3+ TILs (Fig. 2i–k; Extended Data Fig. 3a–c). We 
also observed that palbociclib treatment significantly elevated PD-L1 protein levels in 
various organs of normal mice (Extended Data Fig. 3d–h). Collectively, these results 
demonstrate that cyclin D-CDK4 kinase plays a rate-limiting role in regulating PD-L1 levels 
in vivo.
To understand how cyclin D-CDK4 regulates PD-L1 levels, we first determined that 
treatment of cells with proteasome inhibitor MG132, or with cullin-based ubiquitin E3 ligase 
inhibitor, MLN4924 22 elevated PD-L1 protein levels (Fig. 3a). To identify which cullin 
family E3 ligase(s) regulates PD-L1, we screened the potential interaction of PD-L1 with 
each cullin family proteins and found that Cullin 3, and to a lesser extent, Cullin 1 interacted 
with PD-L1 in cells (Fig. 3b, Extended Data Fig. 4a, b). These results indicate that in 
addition to Cullin 1/β-TRCP 11, Cullin 3-based E3 ligase(s) might play a role in regulating 
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PD-L1 stability. Consistent with this notion, depletion of Cullin 3 elevated the protein 
abundance of endogenous PD-L1 (Extended Data Fig. 4c).
Cullin 3-based E3 ubiquitin ligases recognize their downstream substrates through substrate-
recruiting adaptor proteins 23. We found that SPOP, but not other adaptor proteins examined 
interacted with PD-L1 in cells (Fig. 3c, d). We further determined that deletion of the C-tail, 
or the last eight amino acids of PD-L1 (283-290), disrupted binding of PD-L1 to SPOP, and 
rendered PD-L1 resistant to SPOP-meditated poly-ubiquitination (Extended Data Fig. 4d–h), 
indicating that the 283-290 region of PD-L1 might represent the potential binding motif for 
SPOP. Importantly, the cancer-derived PD-L1 T290M mutant (cBioPortal) located within the 
SPOP-binding motif also lost its ability to interact with SPOP and became more stable 
through decreased SPOP-mediated poly-ubiquitination and degradation (Extended Data Fig. 
4i–l). Furthermore, depleting SPOP or deleting its substrate-interacting MATH domain 
elevated and stabilized PD-L1 in cells (Fig. 3e, f; Extended Data Fig. 5a–m). However, 
depleting known SPOP substrates including AR, ERG, Trim24, or DEK in SPOP-WT or 
SPOP−/− cells did not lead to obvious changes in PD-L1 levels (Extended Data Fig. 5n–u), 
arguing against a possibility of secondary effects for the observed elevation of PD-L1 upon 
SPOP depletion.
SPOP mutations occur in 10–15% of human prostate cancers, and are largely clustered 
within the MATH domain 24,25 (Extended Data Fig. 6a). Notably, these cancer-derived 
SPOP mutants failed to promote PD-L1 degradation due to their deficiency in binding to 
PD-L1 and promoting PD-L1 poly-ubiquitination (Fig. 3g–i and Extended Data Fig. 6b, c), 
which resembles the Elongin C-encoding TCEB1 hotspot mutants in clear cell renal 
carcinoma, resulting in deficiencies in the ability of Cullin 2/Elongin B/C/VHL E3 ligase 
complex to promote HIF1α degradation 26. We also observed that mutations in the PD-L1 
C-tail (degron) are mutually exclusive with mutations in the substrate-interacting MATH 
domain of SPOP (Extended Data Fig. 6d, e).
To further explore the impact of SPOP mutations on tumorigenesis, we generated tumor cell 
lines expressing SPOP-WT or cancer-derived mutants. We found that cells expressing 
cancer-derived SPOP mutants displayed elevated levels of endogenous PD-L1 protein, as 
compared to cells expressing SPOP-WT. (Fig. 3j and Extended Data Fig. 6f–j). Upon 
inoculation into immunoproficient mice, the growth of implanted tumors expressing cancer-
derived SPOP-F102C was faster than tumors expressing SPOP-WT (Fig. 3k and Extended 
Data Fig. 6k). Tumors expressing cancer-derived SPOP-F102C mutant displayed elevated 
PD-L1 levels and significantly reduced numbers of CD3+ TIL (Fig 3l and Extended Data 
Fig. 6l). Strikingly, the difference in tumor weights between SPOP-WT and SPOP-F102C 
groups was largely alleviated after treatment with anti-PD-L1 antibody (Extended Data Fig. 
6m–p), or when tumor cells were inoculated into T cell-deficient Tcrα−/− mice (Extended 
Data Fig. 6q–s). Hence, enhanced tumorigenic potential of SPOP-mutant cells is largely 
caused by elevated PD-L1 levels resulting in increased immune evasion.
We next explored whether loss-of-function SPOP mutations regulate PD-L1 levels or TILs 
in primary human prostate cancers. To this end, we identified 15 SPOP-mutant and 82 
SPOP-wild type tumors through large-scale sequencing as described 27,28. IHC staining 
Zhang et al. Page 4
Nature. Author manuscript; available in PMC 2018 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
results revealed that approximately 80% of SPOP-mutant tumors exhibited strong PD-L1 
staining, while only approximately 10% of SPOP-WT tumors exhibited strong staining for 
PD-L1 and 70% of SPOP-WT cases displayed weak or no PD-L1 staining (Fig. 3m, n; 
Extended Data Fig. 7a–d). Moreover, the numbers of CD8+ TILs were reduced in samples 
harboring SPOP mutations, as compared to SPOP-WT tumors (Fig. 3o; Extended Data Fig. 
7e–h). These results indicate that SPOP-deficiency correlates with elevated PD-L1 protein 
abundance and decreased numbers of TILs in primary human prostate cancers.
We further found that SPOP protein abundance fluctuated during the cell cycle and 
displayed an inverse correlation with PD-L1 protein levels (Fig. 1a and Fig. 4a); depleting 
SPOP resulted in stabilization of PD-L1 across the cell cycle (Fig. 4a and Extended Data 
Fig. 8a). We noted that the Anaphase-Promoting Complex/Cyclosome (APC/C) E3 ligase 
adaptor protein Cdh1 displayed an inverse correlation with SPOP protein levels during cell 
cycle (Fig. 1a, 1c and Fig. 4a). Furthermore, depletion of Cdh1, but not Cdc20, elevated 
SPOP protein abundance, which was accompanied by a simultaneous reduction in PD-L1 
protein levels (Extended Data Fig. 8b, c). Consistent with these results, we detected a 
physical interaction between the endogenous SPOP and Cdh1 proteins (Fig. 4b and 
Extended Data Fig. 8d, e), and identified an evolutionarily conserved destruction-box motif 
(D-box: RxxLxxxxN) 29 in SPOP (Extended Data Fig. 8f). Deleting the D-box motif in 
SPOP disrupted its binding to Cdh1 and rendered SPOP resistant to Cdh1-mediated poly-
ubiquitination and degradation (Fig. 4c, d; Extended Data Fig. 8g–i). Moreover, depletion of 
Cdh1 led to SPOP stabilization, which subsequently resulted in a reduction in PD-L1 protein 
level during cell cycle progression (Fig. 4e). Taken together, these results indicate that Cdh1 
is a physiologically important upstream E3 ligase responsible for negatively regulating 
SPOP protein stability.
To elucidate how the cyclin D-CDK4 kinase affects this mechanism, we established that 
cyclin D1-CDK4 directly phosphorylates SPOP at Ser6, but not Ser222, the only two 
conserved serine-proline sites in SPOP (Fig. 4f and Extended Data Fig. 9a–d). Conversely, 
treatment of cells with CDK4/6 inhibitor, palbociclib, reduced the phosphorylation of SPOP 
in cells (Extended Data Fig. 9e). We observed that 14-3-3γ protein physically interacted 
with SPOP in a pSer6-dependent manner and disrupted the interaction of SPOP with Cdh1 
in cells (Fig. 4g, h; Extended Data Fig. 9f–h). Inhibition of SPOP-pSer6 decreased the 
interaction of SPOP with 14-3-3γ and increased its binding to Cdh1, leading to elevated 
SPOP poly-ubiquitination (Fig. 4i; Extended Data Fig. 9i–p). Consequently, palbociclib 
treatment decreased SPOP protein abundance and elevated PD-L1 levels in SPOP-WT, but 
not SPOP-deficient cells (Fig. 4j). Moreover, depletion of 14-3-3γ dramatically upregulated 
PD-L1 levels and stabilized PD-L1 during cell cycle progression (Extended Data Fig. 9q–t).
Recent clinical studies revealed that the success of PD1/PD-L1 blockade correlates with PD-
L1 expression levels in tumor cells 6,7. Given our observation that inhibition of CDK4/6 
elevated PD-L1 levels, we hypothesized that inhibitors of CDK4/6 kinase might synergize 
with anti-PD-1/PD-L1 therapy to elicit an enhanced therapeutic effect. Notably, we observed 
that treatment of immunoproficient mice bearing CT26 tumors with palbociclib plus anti-
PD-1 antibody dramatically retarded tumor progression and resulted in 8 complete responses 
out of 12 treated mice (Fig. 4k; Extended Data Fig. 10a). Moreover, combining CDK4/6 
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inhibitor with anti-PD-1 therapy resulted in a significant improvement of overall survival 
compared to single-agent treated group (Fig. 4l). Similar results were obtained using mice 
bearing tumors derived from MC38 cells. (Extended Data Fig. 10b, c). As expected from our 
earlier observations, treatment of tumor-bearing mice with palbociclib decreased the 
absolute numbers of TILs, including CD3+, CD4+, CD8+, Granzyme B+ and IFNγ+ cells. 
Importantly, addition of anti-PD-1 antibody to palbociclib treatment restored essentially 
normal numbers of TILs (Extended Data Fig. 10d–j).
A recent study revealed that another inhibitor of CDK4/6, abemaciclib, increased 
immunogenicity of cancer cells via an Rb-dependent mechanism, which activates tumor cell 
expression of endogenous retroviral elements, thereby stimulating production of type III 
interferons and antigen presentation by tumor cells 30. Together with our demonstration that 
cyclin D-CDK4 regulates PD-L1 stability through Cullin 3SPOP (Extended Data Fig. 10k), 
these studies provide complementary molecular rationale for combining CDK4/6 inhibitor 
treatment with anti-PD-1/PD-L1 immunotherapy to enhance tumor regression.
Methods
Cell culture, transfections and viral infections
HEK293T, HEK293, HeLa, MDA-MB-231, MCF7, Hs578T, WT MEFs, cyclin D1−/− 
MEFs, cyclin D2−/− MEFs, cyclin D3−/− MEFs, cyclin D1−/−D2−/−D3−/− MEFs, cyclin 
D1fl/flD2−/−D3fl/fl, Cdk4+/+ and Cdk4−/− MEFs, cyclin A1+/+A2+/+ and cyclin A1−/−A2−/− 
MEFs, cyclin E1+/+E2+/+ and cyclin E1−/−E2−/−, Spop+/+ and Spop−/− MEFs (a kind gift of 
Dr. Nicholas Mitsiadesa, Baylor College of Medicine, Houston, TX) were cultured in 
DMEM medium supplemented with 10% FBS (Gibco), 100 units of penicillin and 100 
μg/ml streptomycin (Gibco). HLF, HepG2, Huh1 and Huh7 were cultured in RPMI medium 
supplemented with 10% FBS. MDA-MB-231 PD-L1 WT and PD-L1 KO cells are kind gift 
from Dr. Mien-Chie Hung. BT549, T47D, ZR75-1, HCC1954, HCC1937, MDA-MB436, 
MDA-MB468 and SKBR3 cells were from Dr. Alex Toker laboratory at BIDMC, Harvard 
Medical School, and cultured in RPMI medium or McCoy’s5A (Corning, NY) medium 
supplemented with 10% FBS. PC3, DU145, 22RV1, LNCaP and C42 were kind gifts from 
Dr. Pier Paolo Pandolfi group at BIDMC, Harvard Medical School, and cultured in RPMI 
medium (Corning, NY) with 10% FBS. Mouse tumor derived MC38 cell line was a kind gift 
from Dr. Arlene Sharpe at Harvard Medical School. Mouse tumor derived 4T1 and B16-F10 
cell lines were routinely cultured in Gordon Freeman’s laboratory in DMEM medium 
supplemented with 10% FBS (Gibco), 100 units of penicillin and 100 μg/ml streptomycin 
(Gibco). All cell lines were routinely tested to be negative for mycoplasma contamination.
Cells with 80% confluence were transfected using lipofectamine plus reagents in Opti-MEM 
medium (Invitrogen). 293FT cells were used for packaging of lentiviral and retroviral cDNA 
expressing viruses, as well as subsequent infection of various cell lines were performed. 
Briefly, medium with secreted viruses were collected twice at 48 hours and 72 hours after 
transfection. After filtering through 0.45 μM filters, viruses were used to infect cells in the 
presence of 4 μg/mL polybrene (Sigma-Aldrich). 48 hours post-infection, cells were split 
and selected using hygromycin B (200 μg/mL) or puromycin (1 μg/mL) for 3 days. Cells 
were harvested and lysed in EBC buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP40) 
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supplemented with protease inhibitors (Roche) and phosphatase inhibitors (Calbiochem) for 
immunoblot analysis.
Reagents
Nocodazole (M1404) and Taxol (T7402) were purchased from Sigma. Thymidine (CAS: 
50-89-5) and cycloheximide (66-81-9) were purchased from Acros organics. Palbociclib 
(PD0332991, S1116) and ribociclib (LEE011, S7440) were purchased from Selleckchem. 
MG132 (BML-PI102-0005) was purchased from Enzo life science. MLN4924 was a kind 
gift from Dr. William Kaelin (Dana-Farber cancer institute).
Plasmids
Myc-tagged Cullin 1, Cullin 2, Cullin 3, Cullin 4A, Cullin 4B, Cullin 5, Flag-tagged SPOP 
WT, Y87C, F102C, W131G, delta MATH, delta BTB, pLenti-HA-SPOP WT, Y87C, F102C, 
W131G, pGEX-4T-1-SPOP, Flag-Keap1, Flag-Cop1, shScramble, shCullin 3, shSPOP, and 
His-ubiquitin constructs were described previously 31. shAR, shERG, shTrim24, shDEK and 
sgSPOP constructs were described previously 31, 32. Myc-Cullin 7 construct was kindly 
offered by Dr. James A. DeCaprio (Dana-Farber Cancer Institute). KLHL2 and KLHL3 
constructs were generous gifts from Dr. Shinichi Uchida (Tokyo Medical and Dental 
University). KLHL12 and KLHL37 constructs were purchased from Addgene. KLHL20 
construct was offered by Dr. Ruey-Hwa Chen (Institute of Biological Chemistry, Academia 
Sinica, Taiwan). The construct of HA-PD-L1 (HA tag in the N-terminus of PD-L1) was 
kindly provided by Dr. Mien-Chie Hung (The University of Texas MD Anderson Cancer 
Center). HA-Cdh1, HA-Cdc20, shCdh1, hCdc20 and HA-14-3-3 isoform constructs were 
described previously 33, 34. pCMV-CDK4 WT, pCMV-CDK4 N158F and shcyclin D3 were 
described previously 35, 36. pBabe-p16 was a kindly gift from Dr. Charles J. Sherr laboratory. 
pLKO-shCDK4 (Plasmid #78153 and #78154) and pMLP-shCDK6 (Plasmid #73552 and 
#73553) were purchased from Addgene. pLKO-sh14-3-3γ (TRCN0000078160, 
TRCN0000078161, TRCN0000078162), pLKO-shp16 (TRCN0000039748, 
TRCN0000039751, TRCN0000039782) and pLKO-shCD8a (TRCN0000057583, 
TRCN0000057587) were purchased from Open Biosystems. pcDNA3-PD-L1, pCMV-GST-
PD-L1-tail (cytoplasmic amino acids), HA-PD-L1-ΔC-tail, HA-PD-L1-Δ283-290, HA-PD-
L1-S283A, HA-PD-L1-S285A, HA-PD-L1-T290M, pLenti-PD-L1 WT, pLenti-PD-L1-
Δ283-290, pLenti-PD-L1 T290M, pET-28a-His-SPOP WT, pET-28a-His-SPOP S6A, 
pET-28a-His-SPOP S22A, Flag-SPOP with delta D-Box (RxxL), pLenti-HA-c-Myc WT, 
pLenti-HA-c-Myc T58A/S62A, pLenti-HA-cyclin D1, pLenti-HA-cyclin D2, pLenti-HA-
cyclin D3, Flag-SPOP S6A, HA-tagged CDK2, CDK4 and CDK6 were generated in this 
study.
Antibodies
Anti-PD-L1 (E1L3N) rabbit mAb (13684), anti-pS10-H3 (3377), anti-pS780-Rb (8180), 
anti-pS807/811-Rb (8516), anti-Rb (9309), anti-cyclin D1 (2978), anti-cyclin D2 (3741), 
anti-CDK6 (3136), anti-cullin 3 (2759), anti-GST (2625), rabbit polyclonal anti-Myc-Tag 
antibody (2278) and mouse monoclonal anti-Myc-Tag (2276) antibodies were purchased 
from Cell Signaling Technology. Mouse PD-L1 antibody (MAB90781-100) was purchased 
from R&D systems. Anti-mPD-L1 for immunoblotting (clone 298B.8E2), anti-mPD-L1 
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(clone 298B.3G6) for immunohistochemistry, and anti-human PD-L1 for 
immunoprecipitation (clone 29E.12B1) were generated in the laboratory of Dr. Gordon J. 
Freeman. Anti-CDK4 (MS-616-P1) was purchased from Thermo Scientific. Anti-SPOP 
(16750-1-AP) was purchased from Proteintech. Anti-cyclin A (sc-751), anti-cyclin B 
(sc-245), anti-cyclin E (SC-247), anti-cyclin D3 (sc-182), anti-Cdh1 (sc56312), anti-Cdc20 
(sc-8358), anti-Cdc20 (sc-13162), anti-Plk1 (sc-17783), anti-TRIM24 (TIF1α, SC-271266), 
anti-HA (sc-805, Y-11), anti-PD-L1 (sc-50298) and anti-GST (sc-459) were obtained from 
Santa Cruz. Anti-GFP (8371-2) was purchased from Clontech. Anti-Flag (F-2425), anti-Flag 
(F-3165, clone M2), anti-Vinculin (V9131), anti-Flag agarose beads (A-2220), anti-HA 
agarose beads (A-2095), peroxidase-conjugated anti-mouse secondary antibody (A-4416) 
and peroxidase-conjugated anti-rabbit secondary antibody (A-4914) were purchased from 
Sigma. Anti-HA (MMS-101P) was obtained from BioLegend.
Immunoblot and immunoprecipitation analyses
Cells were lysed in EBC buffer (50 mM Tris pH 7.5, 120 mM NaCl, 0.5% NP-40) 
supplemented with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors 
(phosphatase inhibitor cocktail set I and II, Calbiochem). Protein concentrations were 
measured by the Beckman Coulter DU-800 spectrophotometer using the Bio-Rad protein 
assay reagent. Equal amounts of protein were resolved by SDS-PAGE and immunoblotted 
with indicated antibodies. For immunoprecipitations analysis, 1000 μg total cell lysates were 
incubated with the primary antibody-conjugated beads for 4 hours at 4 °C. The recovered 
immunocomplexes were washed four times with NETN buffer (20 mM Tris, pH 8.0, 100 
mM NaCl, 1 mM EDTA and 0.5% NP-40) before being resolved by SDS-PAGE and 
immunoblotted with indicated antibodies.
Immunohistochemistry (IHC) for cell pellets, xenografted tumors or human prostate tumor 
specimens
The cultured cells (MDA-MB-231 PD-L1 WT and KO cells; HBP-ALL shScr and shCD8 
cells; KE37 shScr and shCD8 cells) were washed and fixed in 4% paraformaldehyde for 20 
minutes. Cells pellets or xenografted (MDA-MB-231 PD-L1 WT or KO) tumors were 
embedded into TFM and frozen. After cryostat sections (10 μM) were placed on Superfrost 
Plus Stain slides, samples were then permibilized in 0.1% Triton X-100/PBS for 10 minutes. 
For IHC analysis, we used UltraSensitive™ SP (Mouse) IHC Kit (KIT-9701, Fuzhou Maixin 
Biotech) following the manufacturer’s instructions with minor modification. The sections 
were incubated with 3% H2O2 for 15 min at room temperature to block endogenous 
peroxidase activity. After incubating in normal goat serum for 1 hour to block non-specific 
binding of IgG, sections were treated with primary antibody (PD-L1, 298B.3G6, 18 μg/ml; 
CD8α, sc-53212, clone C8/144B, dilution 1:40) at 4°C overnight. Sections were then 
incubated for 30 minutes with biotinylated goat-anti-mouse IgG secondary antibodies 
(Fuzhou Maixin Biotech), followed by incubation with streptavidin-conjugated HRP 
(Fuzhou Maixin Biotech). Specific samples were developed with 3′3-diaminobenzidine 
(DAB-2031, Fuzhou Maixin Biotech). Images were taken using an Olympus microscopic 
camera and matched software.
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The prostate tumor specimens were obtained from Shanghai Changhai Hospital in China. 
Usage of these specimens was approved by the Institute Review Board of Shanghai 
Changhai Hospital. For IHC, the paraformaldehyde fixed paraffin embedded prostate tumor 
samples were deparaffinized in xylene (3 × 10 min), rehydrated through a series of graded 
alcohols (100%, 95%, 85%, and 75%) to water. Samples were then subjected to heat-
mediated antigen retrieval at 95°C for 20 min. The following IHC steps were the same as 
described above.
The expression level of PD-L1 in prostate cancer tumor samples was determined according 
to the intensity of the staining as 0, negative; 1, weak expression; 2, intermediate expression 
and 3, strong expression. The numbers of intraepithelial CD8+ tumor-infiltrating T 
lymphocytes (TILs) was counted as described in Hamanishi et al 37. Briefly, three 
independent areas with the most abundant infiltration were selected under a microscopic 
field at 200 × magnification (0.0625mm2). The number of intraepithelial CD8+ TILs was 
counted manually and calculated as cells per mm2. The Mann-Whitney test was used to 
compare the difference in PD-L1 expression between SPOP mutated and wide type cases. 
The Student’s t test was used to determine P values of the difference in CD8+ TILs between 
SPOP mutated and wide type cases. P < 0.05 was considered as significant.
In vitro cyclin D/CDK4 kinase assays
Kinase assays were performed in a final volume of 30 μl of a kinase buffer as described 
previously 38: 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM DTT, 1 mM EGTA, 0.1 mM 
NaF, containing 10 μM ATP and 0.4 mCi [32P]γATP (Perkin Elmer). 0.2 μg of CDK4/cyclin 
D1 (0142-0143-1, Pro-Qinase), CDK4/cyclin D2 (0142-0375-1, Pro-Qinase), or CDK4/
cyclin D3 (0142-0373-1, Pro-Qinase) were used as kinases. 2 μg of His-SPOP, His-SPOP-
S6A, His-SPOP-S222A, or His-SPOP-S6A/S222A mutant proteins immobilized on Ni-NTA 
beads were used as kinase substrates. 0.1 μg of Rb1 C-terminal recombinant protein (Cat. 
SC-4112, Santa Cruz) was used as a positive control for kinase assays. 2 μg of BSA was 
used as a negative control. After 60 min incubation at 30°C, proteins were denatured, 
resolved on SDS-PAGE, transferred to nitrocellulose membranes and exposed to X-ray 
films.
Kinase assay for Rb by immune-purified endogenous CDK4/cyclin D1 from mice tissues
For endogenous kinase assays, the endogenous CDK4 was immunoprecipitated by 6 μg of 
anti-CDK4 Ab (Santa Cruz, sc-23896 AC) from 2.5 mg of lysates (buffer: 20 mM Tris-HCl 
pH 8.0, 0.1 M KCl, 5 mM MgCl2, 10% glycerol, 0.1% Tween-20, 0.1% NP40) of livers or 
brains isolated from C57BL6 mice. The association of cyclin D1 was also confirmed by 
cyclin D1 antibodies (abcam, ab134175). The immunopurified endogenous CDK4/cyclin D1 
was used as kinase, and 0.5 μg of Rb1 C-terminal recombinant protein (SC-4112) was used 
as the kinase substrate.
In vivo ubiquitination assays
PC3 or HeLa cells with 80% confluence were transfected with His-ubiquitin and the 
indicated constructs. 36 hours post-transfection, cells were treated with 30 μM MG132 for 6 
hours and lysed in buffer A (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, and 10 mM 
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imidazole [pH 8.0]). After sonication, the lysates were incubated with nickel-nitrilotriacetic 
acid (Ni-NTA) beads (QIAGEN) for 3 hours at room temperature. Subsequently, the His 
pull-down products were washed twice with buffer A, twice with buffer A/TI (1 volume 
buffer A and 3 volumes buffer TI), and one time with buffer TI (25 mM Tris-HCl and 20 
mM imidazole [pH 6.8]). The pull-down proteins were resolved by 2 × SDS-PAGE for 
immunoblotting.
Protein half-life assays
Cells were transfected or treated under indicated conditions. For half-life studies, 
cycloheximide (20 μg/ml, Sigma) was added to the medium. At indicated time points 
thereafter, cells were harvested and protein abundances were measured by immunoblot 
analysis.
Cell synchronization and FACS analyses
Cells synchronized with nocodazole arrest and double thymidine treatment as described 
previously 39. Cells synchronized with nocodazole or double thymidine-arrest and release 
were collected at the indicated time points and stained with propidium iodide (Roche) 
according to the manufacturer’s instructions. Cells were fixed by 70% ethanol at −20°C 
overnight and washed 3 times using cold PBS. The samples were digested with RNase for 
30 minutes at 37°C and stained with propidium iodide (Roche) according to the 
manufacturer’s instructions. Stained cells were sorted with BD FACSCanto™ II Flow 
Cytometer. The results were analyzed by ModFit LT 4.1 and FSC express 5 softwares.
BrdU/PI labelling and FACS analyses
Cells were incubated with/without BrdU (75 μM, Sigma) containing medium for 1 hour. 
Cells were harvested and washed once with cold PBS for centrifuge 5 min at 1200 rpm. 
Cells were re-suspended in 200 μl cold PBS and added in 5 ml of cold 90% ethanol for 
fixation overnight. After centrifuge 5 min at 1200 rpm, cells were washed once using 5 ml 
PBS and added in 0.5 ml 2N HCl-0.5% Triton X-100 for 30 min at room temperature (RT). 
After adding in 5 ml PBS, samples were centrifuged for 5 min at 1200 rpm and re-suspended 
in 1 ml Na2B4O7 (pH 8.5). Samples were re-suspended in 200 μl of anti-BrdU diluted (1: 
40) in PBS with 0.5 % tween 20 and 1% BSA and were incubated 30 min at room 
temperature. After adding in 5 ml 20 mM Hepes-PBS (pH7.4) with 0.5% tween 20, samples 
were centrifuged for 5 min at 1200 rpm and were re-suspended in 0.5 ml PBS with 
propidium iodide (PI, 5 μg/ml, Sigma) and RNAse A (200 μg/ml, Roche). After incubating 
30 min at RT, samples were transfered into FACS tube and analyzed by flow cytometry.
Real-Time RT-PCR analyses
Total RNAs were extracted using the QIAGEN RNeasy mini kit, and reverse transcription 
reactions were performed using the ABI Taqman Reverse Transcription Reagents 
(N808-0234). After mixing the generated cDNA templates with primers/probes and ABI 
Taqman Fast Universal PCR Master Mix (4352042), reactions were performed with the 
ABI-7500 Fast Real-time PCR system and SYBR green qPCR Mastermix (600828) from 
Agilent Technologies Stratagene.
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Human GAPDH: Forward, 5′-GGAGCGAGATCCCTCCAAAAT-3′,
Reverse, 5′-GGCTGTTGTCATACTTCTCATGG-3′;
Mouse GAPDH: Forward, 5′-AGGTCGGTGTGAACGGATTTG-3′,
Reverse, 5′-GGGGTCGTTGATGGCAACA-3′;
Human PD-L1: Forward, 5′-TGGCATTTGCTGAACGCATTT-3′,
Reverse, 5′-TGCAGCCAGGTCTAATTGTTTT-3′;
Mouse PD-L1: Forward, 5′-GCTCCAAAGGACTTGTACGTG-3′,
Reverse, 5′-TGATCTGAAGGGCAGCATTTC-3′;
Generation of cyclin D-deficient MEFs
Cyclin D1−/−, D2−/−, D3−/− and D1F/FD2−/−D3F/FMEFs were derived from E13.5 mouse 
embryos as described previously 40, 41.
Generation of mouse tumors
Cyclin D1−/− mice 42 were mated with MMTV-c-Myc or MMTV-Wnt1 mice (from the 
Jackson Laboratory) yielding cyclin D1−/−/MMTV-c-Myc or cyclin D1−/−/MMTV-Wnt1, as 
well as control cyclin D1+/+/MMTV-c-Myc or D1+/+/MMTV-Wnt1 mice. Mammary tumors 
were dissected from multiparous females and snap-frozen.
MMTV-ErbB2 female mice (from the Jackson Laboratory), bred into a mixed C57BL/6 and 
129Sv background, were treated with palbociclib or vehicle only for 6 weeks after detection 
of palpable tumors. Palbociclib was administered daily by gastric gavage (150 mg/kg of 
body weight); every two weeks the daily dose was lowered to 100mg/kg for 2–3 days. 
Control mice were treated with vehicle (10% 0.1N HCl, 10% Cremaphor EL, 20% PEG300, 
60% 50 mM citrate buffer pH 4.5) 10 ml/kg by gastric gavage. After 6 weeks, tumors were 
collected and snap-frozen in OCT.
Treatment of wild-type mice with palbociclib
6-weeks old C57BL/6 female mice (from the Jackson Laboratory) were treated with 
palbociclib (150 mg/kg body weight, by gastric gavage) or vehicle only for 7 days. 
Subsequently, organs were collected and analyzed by immunoblotting.
Mouse tumor implantation
1 × 105 B16-F10 or 2 × 105 MC38 cells were injected subcutaneously into 6-weeks old 
C57BL/6 female mice (from the Jackson Laboratory). Starting one week later, mice were 
treated daily with palbociclib (150 mg/kg body weight, by gastric gavage) or vehicle only, 
for 7 days. Subsequently, tumors were collected and analyzed by FACS or immunoblotting.
1 × 105 B16-F10 cells stably expressing SPOP WT or F102C mutant were injected 
subcutaneously into 6-weeks old C57BL/6 female mice (from the Jackson Laboratory). On 
day 3 after tumor cells were injected, control and PD-L1 mAb treatments were conducted by 
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intra-peritoneal injection (200 μg/mouse in 200 μl HBSS saline buffer) every three days for a 
total of 3 injections. Subsequently, tumors were collected and analyzed by FACS.
1 × 105 B16-F10 cells stably expressing SPOP WT or F102C mutant were injected 
subcutaneously into 6-weeks old Tcrα−/− female mice (from the Jackson Laboratory). After 
10 days, tumors were collected and analyzed by FACS.
Immunofluorescence staining of cells or tumor tissues
MDA-MB-231 PD-L1 WT and KO cells were seeded in chambers (154534, Thermo Fisher 
Scientific). Cells were fixed with 4% paraformaldehyde for 20 minutes, followed with 0.1% 
Triton X-100 in PBS for 10 minutes. Cells were pre-blocked with 2% BSA/PBS for 45 
minutes, then incubated with primary antibodies against PD-L1 (PD-L1, 298B.3G6, 1:200), 
for 2.5 hours at room temperature and followed with secondary anti-mouse antibodies 
conjugated with Alexa-fluor-568 (Invitrogen, 1:250). Hoechst (life technology, 1:10,000) 
was used to stain nuclei.
TFM-embedded 10 μM-thick tumor tissue sections were fixed with 2% 
paraformaldehyde/PBS for 30 min, and permeabilized in 0.1% Triton X-100/PBS for 10 
min. Tumor tissue sections were pre-blocked with 2% BSA/PBS for 45 min, then incubated 
with primary antibodies against PD-L1 (1:200), CD3 (Abcam, 1:250) for 2.5 hours at room 
temperature and followed with secondary anti-mouse antibodies conjugated with Alexa-
fluor-568 (Invitrogen, 1:250) and anti-rabbit antibodies conjugated with Alexa-fluor-488 
(Invitrogen, 1:250). Hoechst (life technology, 1:10,000) was used to stain nucleus. Tumor 
tissues were mounted with fluoromount-G® (SouthernBiotech) at 4°C overnight. Tissue 
sections were examined with fluorescent microscope under a 20 × objective lens. CD3+ cell 
numbers were counted in an area of 5.95 × 105 μm2.
Single cell generation from tumor tissue and flow cytometry analysis
Tumor tissues were minced and digested with 5 ml of 2 mg/ml collagenase (Sigma) in 
DMEM for 1 hour at 37°C. Cells were then collected by centrifuge and filtered through a 70 
μm strainer in DMEM. Cell pellets were suspended and lysed in red blood cell lysis buffer 
for 5 min. The cells were then filtered through a 40 μm strainer in 1 x PBS with 2% BSA. 1 
million cells were incubated with antibodies against PD-L1 (564715, BD Biosciences, 
1:100) conjugated with APC or antibodies against CD3 (Biolegend, 1:100) conjugated with 
APC or corresponding isotype IgG1 control at room temperature for 30 min. Cells were 
washed by 1 x PBS with 2% BSA and analyzed by flow cytometry.
In vivo experimental therapy in MC38 and CT26 mice tumor models
Animal studies were approved by Dana-Farber Cancer Institute Institutional Animal Care 
and Use Committee (IACUC; protocol number 04-047), and performed in accordance with 
guidelines established by NIH Guide for the care and use of laboratory animals. MC38 or 
CT26 tumors were established by subcutaneously injecting 1 × 105 MC38 or CT26 tumor 
cells in 100 μl HBSS into the right flank of 6-week old C57BL/6 or BALB/c female mice 
(Jackson Lab, ME). Tumor sizes were measured every three days by caliper after 
implantation and tumor volume was calculated by length × width2 × 0.5. On day 7 after 
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tumor cells were injected, animals were pooled and randomly divided into four groups with 
comparable average tumor size. Moreover, the lab members who measured the mice were 
blinded to the treatment groups. Mice were grouped into control antibody treatment, PD-1 
mAb treatment, CDK4/6 inhibitor treatment, and PD-1 mAb plus CDK4/6 inhibitor 
treatment. As illustrated in Extended Data Fig. 10a, control and PD-1 mAb treatments were 
conducted by intraperitoneal injection (200 μg/mouse in 200 μl HBSS saline buffer) every 
three days for a total of 8 injections. The CDK4/6 inhibitor treatment was given by oral 
gavage once a day with a dosage of 100 mg/kg for three weeks with a break every week for 
one day. For survival studies, animals were monitored for tumor volumes every three days 
for 120 days after initial treatment, until tumor volume exceeded 2000 mm3, or until tumor 
had ulcer with diameter reached 1 cm. Statistical analysis was conducted using the 
GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). Kaplan-Meier curves 
and corresponding Gehan-Breslow-Wilcoxo tests were used to evaluate the statistical 
differences between groups in survival studies. P < 0.05 was considered to be significant.
T cell analysis for MC38 implanted tumors
MC38 implanted tumors were established by subcutaneously injecting 1 × 105 of MC38 
cells were injected into the right flank of 6 week old C57BL/6 female mice (Jackson Lab). 
On the day of the tumor cells injected, mice were randomly divided into four groups: control 
antibody treatment, PD-1 mAb treatment, CDK4/6 inhibitor treatment, and PD-1 mAb plus 
CDK4/6 inhibitor treatment. Control and PD-1 mAb treatments were conducted by 
intraperitoneal injection (200 μg/mouse in 200 μl HBSS saline buffer) every three days for a 
total of 4 injections. The treatment of palbociclib was given by oral gavage with the dosage 
of 200 mg/kg for 9 days, with a break after 7 days. Tumors were then collected and single 
cell was generated from tumor tissues as described in section “Single Cell Generation from 
Tumor Tissue and Flow Cytometry analysis”. After cells were filtered through 40 μm 
strainer, cells were fixed in 0.5 ml/tube Fixation buffer (420801, Biolegend) in the dark for 
20 minutes at room temperature. Cells were then washed with 1 × PBS with 2% BSA. The 
fixed cells were suspended in Intracellular Staining Perm Wash Buffer (421002, Biolegend) 
after centrifuge for two times to permeabilize the cells. Cells were then co-stained with 
antibodies against CD3 (100236, APC conjugated, Biolegend), Granzyme B (515403, FITC 
conjugated, Biolegend), IFN-γ (505808, PE conjugated, Biolegend) to check the activities 
of T cells. Or cells were co-stained with antibodies against CD3 (100236, APC conjugated, 
Biolegend), CD4 (100510, FITC conjugated, Biolegend), CD8 (100708, PE conjugated, 
Biolegend). The corresponding isotype IgG1 controls were used for controls. The cells were 
incubated with corresponding antibodies for 30 minutes at room temperature. Cells were 
washed by 1 × PBS with 2% BSA and analyzed by flow cytometry.
Data Availability Statement (DAS)
Source data for gels in Figs 1–4 and Extended Data Figs. 1–9 are available in Supplementary 
Fig. 1. Source data for Figs 2j and 2k are available in Table 1. Source data for Figs 3j–n, 3o 
are available in Table 2. Source data for Figs 4k, l are available in Table 3. Source data for 
Extended Data Figs 3c, d are available in Table 4. Source data for Extended Data Figs 6j, l, 
o, p, r, s are available in Table 5. Source data for Extended Data Figs 10b–j are available in 
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Table 6. All other data supporting the findings of this study are available from the 
corresponding author upon a reasonable request.
Extended Data
Extended Data Figure 1. PD-L1 fluctuates during cell cycle progression
a, b, Immunoblot (IB) of whole cell lysates (WCL) derived from MDA-MB-231 or 
HCC1954 cells synchronized in M phase by nocodazole treatment prior to releasing back 
into the cell cycle for the indicated times.
c, d, Quantitative real-time PCR (qRT-PCR) analyses of relative mRNA levels of PD-L1 and 
GAPDH from samples derived from HeLa cells synchronized in M phase by nocodazole 
treatment prior to releasing back to the cell cycle for the indicated time points.
e, IB of WCL derived from HeLa cells pre-treated with/without IFNγ (10 ng/ml) for 12 
hours and then synchronized in M phase by nocodazole treatment prior to releasing back 
into the cell cycle for the indicated times.
f, IB of WCL derived from HeLa cells stably expressing HA-c-Myc WT, or HA-T58A/
S62A-c-Myc as well as empty vector (EV) as a negative control.
g, IB of WCL derived from HeLa cells with/without stably expressing HA-c-Myc WT 
synchronized in M phase by nocodazole treatment prior to releasing back into the cell cycle 
for the indicated times.
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h–j, IB of WCL derived from MC38, CT26, 4T1, or B16-F10 mouse tumor cells treated 
with the indicated concentration of nocodazole for 20 hours before harvesting. (k–m) IB of 
WCL derived from B16-F10, 4T1, or CT26 mouse tumor cells treated with the indicated 
concentration of taxol for 20 hours before harvesting.
Extended Data Figure 2. Cyclin D/CDK4 negatively regulates PD-L1 protein stability
a, b, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from wild type (WT), 
cyclin A1−/−A2−/− or WT, cyclin E1−/−E2−/− MEFs.
c, Quantitative real-time PCR (qRT-PCR) analysis of relative mRNA levels of PD-L1 from 
wild type MEFs and cyclin D1−/−D2−/−D3−/− MEFs. Data were represented as mean ± s.d, n 
= 5.
d, Cell cycle profiles for WT and cyclin D1−/−D2−/−D3−/− MEFs, which were labeled with 
BrdU and analyzed by FACS.
e, IB analysis of WCL derived from cyclin D1fl/flD2−/−D3fl/fl MEFs with or without 
depleting cyclin D1 and cyclin D3 by pLenti-Cre via viral infection (pLenti-EGFP as a 
negative control), selected with puromycin (1 μg/ml) for 72 hours before harvesting.
f, IB analysis of WCL derived from cyclin D1−/−D2−/−D3−/− MEFs stably reintroducing 
cyclin D1, cyclin D2, or cyclin D3, respectively, with empty vector (EV) as a negative 
control.
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g, IB analysis of WCL derived from mouse mammary tumors induced by MMTV-c-Myc 
with/without genetic depletion of cyclin D1. n = 5 mice per experimental group.
h, IB analysis of WCL derived from WCL derived from wild type and cdk6−/− MEFs.
i, j, IB analysis of WCL derived from MDA-MB-231 cells stably expressing shCDK6 or 
shCDK2 as well as shScr as a negative control, respectively.
k, l, IB analysis of WCL derived from MDA-MB-231 cells transfected with indicated 
constructs (k) and the intensity of PD-L1 band was quantified by the ImageJ software (l).
m, IB analysis of WCL derived from MDA-MB-231 cells depleted of Rb (with shScr as a 
negative control) treated with the CDK4/6 inhibitor, palbociclib, where indicated.
n, o, IB analysis of WCL derived from mouse CT26 or 4T1 tumor cell lines treated with or 
without the CDK4/6 inhibitor, palbociclib or ribociclib, respectively.
p, q, IB analysis of WCL derived from MDA-MB-231 cells pre-treated with palbociclib (1 
μM) for 36 hours before treatment with cycloheximide (CHX) for the indicated time points 
(p) and PD-L1 protein abundance was quantified by the ImageJ and plotted as indicated (q).
r, IB analysis of WCL derived from 19 different cancer cell lines with indicated antibodies.
s–u, IB analysis of WCL derived from MCF7, T47D or HLF stably expressing p16 as well 
as EV as a negative control.
v–x, IB analysis of WCL derived from MDA-MB-436, BT549 or HCC1937 stably 
expressing three independent shRNAs against p16 as well as shScr as a negative control.
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Extended Data Figure 3. CDK4/6 inhibitor, palbociclib, treatment elevated PD-L1 levels in vivo
a, b, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from MC38 or B16-F10 
mouse tumor cell line implanted tumors treated with palbociclib (150 mg/kg body weight, 
by gastric gavage) or vehicle for 7 days. n = 5 mice per experimental group.
c, FACS analysis for PD-L1 or CD3+ T-cell populations from MC38 implanted tumors 
treated with vehicle or palbociclib for 7 days. n = 5 mice per experimental group.
d, IB analysis of WCL derived from multiple organs in mice treated with palbociclib (150 
mg/kg body weight, by gastric gavage) or vehicle for 7 days. n = 5 mice per experimental 
group.
e, Quantification of PD-L1 protein bands intensity in Extended Data Fig. 3d by using the 
ImageJ software. n = 5 mice per experimental group.
f, IB analysis of WCL derived from 15 different tissues with/without palbociclib treatment 
and MMTV-c-Myc induced breast tumors.
g, Quantification of PD-L1 protein bands intensity in Extended Data Fig. 3f by using the 
ImageJ software. n = 3 biological replicates
h, In vitro kinase assay for Rb through using immunoprecipitated CDK4/cyclin D kinase 
complex from liver or brain by anti-CDK4 antibody IP. Note that cyclin D-CDK4 complex 
in non-dividing organs (livers and brains) displayed kinase activity, which might explain 
why CDK4/6 inhibitor elevated PD-L1 in these organs. Error bars, ± s.d., two-tailed t-test, 
*P < 0.05, **P < 0.01, ***P < 0.001.
Extended Data Figure 4. Cullin 3SPOP promotes PD-L1 ubiquitination and subsequent 
degradation largely through interaction with the cytoplasmic tail of PD-L1
a, A schematic illustration of PD-L1 with N-terminal signal peptide, extracellular domain, 
trans-membrane domain, cytoplasmic tail and the potential SPOP-binding motif in PD-L1.
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b, d, Immunoblot (IB) analysis of whole cell lysates (WCL) and GST pull-down precipitates 
derived from 293T cells transfected with indicated constructs and treated with MG132 (10 
μM) for 12 hours before harvesting.
c, IB analysis of WCL derived from PC3 stably expressing shCullin 3.
e, g, IB analysis of WCL and immunoprecipitation (IP) derived from 293T cells transfected 
with indicated constructs and treated with MG132 (10 μM) for 12 hours before harvesting.
f, IB of WCL and Ni-NTA pull-down products derived from the lysates of PC3 cells 
transfected with the indicated constructs. Cells were treated with MG132 (30 μM) for 6 
hours before harvesting and lysed in the denature buffer.
h, IB analysis of WCL and IP derived from 293T cells transfected with indicated constructs 
and treated with MG132 (10 μM) for 12 hours before harvesting.
i, IB of WCL derived from MDA-MB-231 PD-L1 KO cells stably expressing PD-L1 WT, 
delta 283-290, T290M as well as EV as a negative control.
j, IB analysis of WCL derived from 293T cells transfected with HA-PD-L1 WT and the 
T290M mutant, which were treated with cycloheximide (CHX) for indicated time points 
before harvesting.
k, IB of WCL and Ni-NTA pull-down products derived from the lysates of PC3 cells 
transfected with the indicated constructs. Cells were treated with MG132 (30 μM) for 6 
hours before harvesting and lysed in the denaturing buffer.
l, IB of WCL derived from 293T cells transfected with indicated constructs.
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Extended Data Figure 5. SPOP negatively regulates PD-L1 protein stability in a poly-
ubiquitination dependent manner
a–c, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from 293T cells 
transfected with indicated constructs.
d, e, IB analysis of WCL derived from 293T cells transfected with indicated constructs. 36 h 
post transfection, cells were treated with 20 μg/ml cycloheximide (CHX) at indicated time 
points (d). The PD-L1 protein abundance were quantified by the ImageJ software and 
plotted (e).
f, IB of WCL and Ni-NTA pull-down products derived from the lysates of PC3 cells 
transfected with the indicated constructs. Cells were treated with MG132 (30 μM) for 6 
hours before harvesting and lysed in the denaturing buffer.
g, A schematic illustration of SPOP with MATH and BTB domain to interact with substrate 
and Cullin 3, respectively.
h, IB analysis of WCL and IP derived from 293T cells transfected with indicated constructs 
and treated with MG132 (10 μM) for 12 hours before harvesting.
i IB analysis of WCL derived from 293T cells transfected with indicated constructs.
j, qRT-PCR analysis of relative mRNA levels of PD-L1 from Spop+/+ and Spop−/− MEFs. 
Data were represented as mean ± s.d, n=5.
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k, IB analysis of WCL derived from PC3 cells infected with indicated lentiviral shRNAs 
against SPOP and selected with puromycin (1 μg/ml) for 72 hours before harvesting.
l–m, IB analysis of WCL derived from C42 cells with depletion of SPOP using sgRNA and 
treated with cycloheximide (CHX) for indicated time points before harvesting (l). The PD-
L1 protein abundance were quantified by the ImageJ software and plotted (m).
n, o, IB analysis of WCL derived from LNCaP cells stably expressing shAR or shERG as 
well as shScr as a negative control.
p, q, IB analysis of WCL derived from DU145 cells stably expressing shTrim24 or shDEK 
as well as shScr as a negative control.
r–u, IB analysis of WCL derived from C42 SPOP WT and SPOP−/− cells that stably 
expressed shAR, shERG, shTrim24, or shDEK as well as shScr, respectively.
Extended Data Figure 6. Cancer-derived SPOP mutations fail to promote PD-L1 degradation
a, The mutation frequency (mutated cases/total cases) of SPOP across 24 cancer types from 
the TCGA database. Mutations are categorized as happening in the MATH domain, in the 
BTB domain or at any other position of the gene, including UTRs. Because some patient 
cases contain mutations of two or three categories, the proportion of three colors are 
allocated mutation-wise, instead of case-wise.
b, The distribution of mutation positions of SPOP in 24 cancer types from the TCGA 
database. Mutations with low translational consequences have been discarded.
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c, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from 293T cells 
transfected with indicated constructs.
d, The mutation frequency (mutated cases/total cases) of PD-L1 (CD274) across 19 cancer 
types from the TCGA database.
e, Oncoplot of PD-L1 (CD274) and SPOP across all 39 cancer types in the TCGA database. 
Only mutations or truncations in the C terminal tail of PD-L1 or in the MATH domain of 
SPOP are counted.
f, IB of WCL derived from B16-F10 mouse tumor cell line stably expressing the indicated 
SPOP constructs.
g, h, Growth curve and cell cycle profile of B16-F10 cells stably expressing SPOP WT and 
the F102C mutant as well as EV as a negative control.
i, Cell cycle profile of 22Rv1 cells stably expressing SPOP WT and the F102C mutant as 
well as EV as a negative control.
j, Relative cell surface PD-L1 expression of 4T1 implanted tumors ectopically expressing 
SPOP-WT or the SPOP-F102C mutant were subjected to FACS analysis. n = 5 mice per 
experimental group.
k, B16-F10 cells stably expressing SPOP-WT or the SPOP-F102C mutant implanted tumors 
from C57BL/6 mice were dissected and taken a picture after euthanizing the mice.
l, The number of CD3+ T-cell populations from the isolated tumor-infiltrating lymphocytes 
in 4T1 cells stably expressing SPOP-WT or the SPOP-F102C mutants implanted tumors 
were subjected to FACS analysis. n = 5 mice per experimental group.
m, B16-F10 cells stably expressing SPOP-WT or the SPOP-F102C mutant implanted 
tumors from C57BL/6 mice treated with anti-PD-L1 antibody were dissected and taken a 
picture after euthanizing the mice. n = 7 mice per experimental group.
n, The weight of B16-F10 cells implanted tumors from C57BL/6 mice treated with anti-PD-
L1 antibody. 12 mice per experimental group.
o, Relative cell surface PD-L1 expression of B16-F10 cells implanted tumors ectopically 
expressing SPOP-WT or the SPOP-F102C mutant treated with anti-PD-L1 antibody were 
subjected to FACS analysis. n = 5 mice per experimental group.
p, The number of CD3+ T-cell populations from the isolated tumor-infiltrating lymphocytes 
in B16-F10 cells implanted tumors ectopically expressing SPOP-WT or the SPOP-F102C 
mutant treated with control IgG or anti-PD-L1 antibody were subjected to FACS analysis. n 
= 7 mice per experimental group.
q, B16-F10 cells stably expressing SPOP-WT or the SPOP-F102C mutant implanted tumors 
from Tcrα−/− mice were dissected and taken a picture after euthanizing the mice. n = 7 mice 
per experimental group.
r, Relative cell surface PD-L1 expression of B16-F10 cells stably ectopically expressing 
SPOP-WT or the SPOP-F102C mutant implanted tumors from Tcrα−/− mice were subjected 
to FACS analysis. n = 7 mice per experimental group.
s, The number of CD3+ T-cell populations from the isolated tumor-infiltrating lymphocytes 
in B16-F10 cells stably ectopically expressing SPOP-WT or the SPOP-F102C mutant 
implanted tumors from Tcrα−/− mice were subjected to FACS analysis. n = 7 mice per 
experimental group. Error bars, ± s.d., two-tailed t-test, *P < 0.05, **P < 0.01, ***P < 0.001, 
NS: no significance.
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Extended Data Figure 7. Validation of anti-PD-L1 and anti-CD8 antibodies through using PD-L1 
KO or shCD8 cells
a, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from MDA-MB-231 cells 
depleted PD-L1 through the CRISPR-Cas9 system.
b, Immunofluorescence (IF) for MDA-MB-231 PD-L1 WT and KO cells using the anti-PD-
L1 antibody. The scale bar represents 50 μm.
c, d, Immunochemistry (IHC) for MDA-MB-231 PD-L1 WT and KO cells from cultured on 
glass slides (c) or implanted tumors (d) using the anti-PD-L1 antibody. The scale bar 
represents 50 μm.
e, f, IB analysis of WCL derived from HBP-ALL (e) or KE37 (f) cells stably expressing 
shCD8 as well as shScr as a negative control using the anti-CD8 antibody.
g, h, IHC for HBP-ALL (g) or KE37 (h) cell pellets stably expressing shCD8 as well as 
shScr as a negative control using the anti-CD8 antibody. The scale bar represents 50 μm.
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Extended Data Figure 8. Depletion of Cdh1, but not Cdc20, prolongs SPOP proteins stability, 
which is simultaneously coupled with a decrease in PD-L1 protein level
a–c, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from HeLa depleted 
SPOP through the CRISPR-Cas9 system (a) or depleted Cdc20 or Cdh1 through multiple 
independent shRNAs (b, c).
d, IB analysis of WCL and immunoprecipitation (IP) derived from 293T cells transfected 
with indicated constructs and treated with MG132 (10 μM) for 12 hours before harvesting.
e, IB analysis of WCL and IP derived from HeLa cells treated with MG132 (10 μM) for 12 
hours before harvesting.
f, A sequence comparison of D-box motif (RxxLxxxxN) in SPOP derived from different 
species.
g, IB analysis of WCL derived from HeLa cells transfected with indicated constructs.
h, i, IB analysis of WCL derived from 293T cells transfected with indicated constructs. 36 h 
post transfection, cells were treated with cycloheximide (CHX) as indicated time points 
before harvesting (h). The protein abundance of SPOP-WT and deletion of RxxL mutant 
were quantified by the ImageJ software (i).
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Extended Data Figure 9. Cyclin D/CDK4-mediated phosphorylation of SPOP at the Ser6 residue 
promotes its binding with 14-3-3γ to reduce its poly-ubiquitination and subsequent degradation 
by APC/Cdh1
a, A sequence comparison of conserved SP sites and putative 14-3-3γ binding motif in 
SPOP.
b, Immunoblot (IB) analysis of whole cell lysates (WCL) and immunoprecipitation (IP) 
derived from 293T cells transfected with indicated constructs and treated with MG132 (10 
μM) for 12 hours before harvesting.
c, d, In vitro kinase assays with recombinant Rb and SPOP as substrates and cyclin D1/
CDK4, cyclin D2/CDK4 and cyclin D3/CDK4 as kinase complex were performed. BSA was 
used as a negative control where indicated.
e, IB analysis of WCL and immunoprecipitation (IP) derived from MDA-MB-231 cells 
transfected with indicated constructs, which were treated with/without palbociclib (1 μM) 
for 12 hours.
f, Streptavidin beads pull-down assay for biotin-labeled SPOP peptide with/without 
phosphorylation at the Ser6 residue to examine its in vitro association with 14-3-3γ.
g, IB analysis of WCL and GST pull-down precipitates derived from 293T cells transfected 
with indicated constructs and treated with MG132 (10 μM) for 12 hours before harvesting.
h, i, IB analysis of WCL and IP derived from 293T cells transfected with indicated 
constructs and treated with MG132 (10 μM) for 12 hours before harvesting.
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j, k, IB analysis of WCL derived from 293T cells transfected with indicated constructs. 36 h 
post transfection, cells were treated with 20 μg/ml cycloheximide (CHX) as indicated time 
points (j). The protein abundance of SPOP-WT and S6A mutant were quantified by the 
ImageJ software and plotted accordingly (k).
l, p, IB of WCL and Ni-NTA pull-down products derived from the lysates of PC3 cells 
transfected with the indicated constructs. Cells were treated with MG132 (30 μM) for 6 
hours before harvesting and lysed in the denaturing buffer for following assay.
m–o, IB analysis of WCL and IP derived from 293T cells transfected with indicated 
constructs and treated with MG132 (10 μM) and with/without palbociclib (1 μM) for 12 
hours before harvesting.
q–s, IB of WCLs derived from PC3, BT549 and HeLa cells stably expressing sh14-3-3γ as 
well as shScr as a negative control.
t, IB of WCL derived from HeLa cells stably expressing shScr or sh14-3-3γ synchronized in 
M phase by nocodazole treatment prior to releasing back into the cell cycle for the indicated 
times.
Extended Data Figure 10. Combination therapy of anti-PD-1 mAb and CDK4/6 inhibitor in 
MC38 colon cancer mouse model
a, A schematic model that illustrates the treatment plan for mice bearing subcutaneous 
MC38 tumors. Female C57BL/6 mice were implanted with 0.1 × 106 MC38 cells 
subcutaneously and treated with four arms: control antibody treatment, anti-PD-1 mAb 
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treatment, CDK4/6 inhibitor treatment, anti-PD-1 mAb plus CDK4/6 inhibitor combination 
treatment.
b, MC38 implanted tumor-bearing mice were enrolled in different treatment groups as 
indicated. Tumor volumes of mice treated with control antibody (n = 15), anti-PD-1 mAb (n 
= 15), the CDK4/6 inhibitor, palbociclib (n = 14) or combined therapy (n = 12) were 
measured every three days and plotted individually. We repeated this experiment twice.
c, Kaplan-Meier survival curves for each treatment group demonstrate the improved efficacy 
of combining PD-1 mAb with the CDK4/6 inhibitor, palbociclib. *P < 0.05. (Gehan-
Breslow-Wilcoxo test). We repeated this experiment twice.
d, e, g, i, The absolute number of CD3+, CD4+, CD8+, Granzyme B+, or IFNγ+ TILs cells 
of implanted MC38 tumors treated with indicated agents was analyzed by FACS. Control: n 
= 8, palbociclib: n = 10, PD-1 Ab: n = 9, Palbociclib & PD-1 Ab: n = 8.
f, h, j, The percentage of CD4+, CD8+ in CD3+ TILs cells of implanted MC38 tumors 
treated with indicated agents was analyzed by FACS. Control: n = 8, palbociclib: n = 10, 
PD-1 Ab: n = 9, Palbociclib & PD-1 Ab: n = 8.
k, A proposed working model to illustrate how PD-L1 protein stability is regulated by the 
cyclin D/CDK4-SPOP-Cdh1 signaling pathway. The cyclin D/CDK4 negatively regulates 
PD-L1 protein stability largely through phosphorylating its upstream physiological E3 ligase 
SPOP to promote SPOP binding with 14-3-3γ, which subsequently disrupts Cdh1-mediated 
destruction of SPOP. As such, CDK4/6 inhibitor treatment could unexpectedly elevate PD-
L1 protein levels largely through inhibiting cyclin D/CDK4-mediated phosphorylation of 
SPOP to promote its degradation by APC/CCdh1. The unexpected rise of PD-L1 could 
present a severe clinical problem for patients receiving CDK4 inhibitor treatment and could 
be one of the underlying mechanisms accounting for CDK4 inhibitor resistance via evading 
immune surveillance checkpoint. Hence, our work provides a novel molecular mechanism as 
well as the rationale for the combinational treatment of PD-L1 blockage treatment and the 
CDK4/6 inhibitors as a more efficient anti-cancer clinical option. Error bars, ± s.d., two-
tailed t-test, *P < 0.05, **P < 0.01, ***P < 0.001, NS: no significance.
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Figure 1. The protein abundance of PD-L1 fluctuates during cell cycle progression
a, c, Immunoblot (IB) analysis of whole cell lysates (WCL) derived from HeLa cells 
synchronized in M phase by nocodazole (a) or in late G1/S phase by double thymidine (b) 
following by releasing back into the cell cycle.
b, d, The cell-cycle profiles in (a) or (c) were monitored by fluorescence-activated cell 
sorting (FACS).
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Figure 2. Cyclin D-CDK4 negatively regulates PD-L1 protein stability
a–d, IB analysis of WCL derived from wild type versus combinational (cyclin 
D1−/−D2−/−D3−/−) (a) or single isoform cyclin D knockout MEFs (b), MDA-MB-231 cells 
depleted cyclin D1 or cyclin D3 using shRNAs (c), or MMTV-Wnt1 induced mouse 
mammary tumors with/without genetic depletion of cyclin D1 (d).
e–h, IB analysis of WCL derived from wild type versus cdk4−/− MEFs (e), MDA-MB-231 
cells depleted CDK4 using shRNAs (f), or multiple breast cancer cell lines treated with 
palbociclib (0.5, 1 μM) for 48 hours (g, h).
i, j, Immunofluorescence staining of PD-L1 and CD3 in mouse mammary tumors induced 
by MMTV-ErbB2 treated with vehicle or palbociclib as described in Method (i) and the 
quantification of CD3+ T cell population (j). The scale bar: 50 μm.
k, FACS analysis for PD-L1 or CD3+ T-cell populations from MC38 implanted tumors 
treated with vehicle or palbociclib for 7 days. Vehicle, n = 4 for (i, j) or 7 mice for (k); 
palbociclib, n = 4 for (i, j) or 7 mice for (k). Error bars, ± s.d., two-tailed t-test, **P < 0.01, 
***P < 0.001 (two-tailed t-test).
Zhang et al. Page 30
Nature. Author manuscript; available in PMC 2018 May 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Cullin 3SPOP is the physiological E3 ubiquitin ligase for PD-L1
a–d, IB analysis of WCL derived from C4-2 cells treated with MG132 (10 μM) or 
MLN4924 (1 μM) for 12 hours (a), immunoprecipitates (IP) and WCL derived from 293T 
cells transfected with indicated constructs (b, d), or anti-PD-L1 IP and WCL derived from 
PC3 cells (e). Cells were treated with MG132 (10 μM) for 12 hours in b, c.
e–g, IB analysis of WCL derived from Spop+/+ versus Spop−/− MEFs (e), C4-2 cells 
depleted SPOP with sgRNAs (f), or C4-2 cells stably expressing indicated SPOP WT and 
mutants (g).
h, i, IB analysis of IP and WCL derived from 293T cells (h), or Ni-NTA pull-down products 
derived from PC3 cells transfected with indicated constructs and treated with 30 μM MG132 
for 6 hours.
j–l, FACS analysis for PD-L1 (j) or CD3+ T-cell population (l) of the B16-F10 implanted 
tumors ectopically expressing SPOP-WT or F102C mutant (n = 6 mice each group). Tumor 
weight were recorded at the time of sacrifice (k) (n = 5 mice each group).
m, Representative images of PD-L1 and CD8 immunohistochemistry (IHC) staining in 
SPOP wild-type or mutant primary human prostate cancer samples. The scale bar: 400 μm or 
100 μm.
n, o Quantification of IHC analysis for PD-L1 (n) and CD8+ T cells (o) in SPOP wild-type 
versus mutant human prostate tumor specimens. (n =15 for SPOP mutant, n = 82 for SPOP 
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WT). Error bars, ± s.d., two-tailed t-test, except (n) Mann-Whitney test, *P < 0.05, **P < 
0.01, ***P < 0.001.
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Figure 4. Cyclin D-CDK4-mediated phosphorylation of SPOP stabilizes SPOP largely through 
recruiting 14-3-3γ to disrupt its binding with Cdh1
a–e, IB of WCL derived from HeLa cells with/without depletion of SPOP (a) or Cdh1 (e) 
synchronized in M phase by nocodazole treatment prior to releasing for the indicated times, 
IP and WCL derived from MDA-MB-231 (b) or 293T (c) cells, or Ni-NTA pull-down 
products derived from HeLa cells transfected with the indicated constructs (d). Cells were 
treated with MG132 (30 μM) for 6 hours in b–d.
f, In vitro kinase assays showing that cyclin D1/CDK4 phosphorylates recombinant SPOP at 
Ser6, not Ser222.
g–j, IB analysis of IP and WCL derived from 293T cells transfected with indicated 
constructs and treated with MG132 (10 μM) or with/without palbociclib (1 μM) for 12 hours 
(g–i), or HeLa cells with/without depletion of SPOP treated with palbociclib (0.5, 1 μM) for 
48 hours (j).
k, CT26 implanted tumor-bearing mice were enrolled in different treatment groups as 
indicated. Tumor volumes of mice treated with control antibody (n = 13), anti-PD-1 mAb (n 
= 14), the CDK4/6 inhibitor, palbociclib (n = 12) or combined therapy (n = 12) were 
measured every three days and plotted individually. We repeated this experiment twice.
l, Kaplan-Meier survival curves for each treatment group demonstrate the improved efficacy 
of combining PD-1 mAb with the CDK4/6 inhibitor, palbociclib. ***P < 0.001. (Gehan-
Breslow-Wilcoxo test). We repeated this experiment twice.
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